Therapeutics News and Research

RSS

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

Study provides new insight on cancer prevention

Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?

4 Feb 2013

Study shows how placental circulation can influence malarial parasite behavior and infection

Malaria in pregnancy causes a range of adverse effects, including abortions, stillbirths, premature delivery and low infant birth weight. Many of these effects are thought to derive from a placental inflammatory response resulting from interaction of infected red blood cells with the placental tissue.

3 Feb 2013

Two new methods could accelerate development of improved antisense drugs

Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases. Though antisense therapy has been proven effective, challenges remain in ensuring that the drugs reach their intended targets.

2 Feb 2013

Study shows how female steroid hormones can make changes to the breast genetic material

Melbourne scientists have discovered how female steroid hormones can make dramatic changes to the genetic material in breast cells, changes that could potentially lead to breast cancer.

2 Feb 2013

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.

1 Feb 2013

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

UC Irvine biologists, chemists and computer scientists have identified an elusive pocket on the surface of the p53 protein that can be targeted by cancer-fighting drugs. The finding heralds a new treatment approach, as mutant forms of this protein are implicated in nearly 40 percent of diagnosed cases of cancer, which kills more than half a million Americans each year.

1 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

Gene variant boosts ulcer susceptibility in NSAID users

A single nucleotide polymorphism in the cytochrome P450 2C gene cluster influences the risk for peptic ulcer disease in people taking non-steroidal anti-inflammatory drugs, a study reveals.

31 Jan 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Cell Therapeutics, Inc. (CTI) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

31 Jan 2013

Silibinin kills skin cells mutated by UVA radiation and protects against cancer

A pair of University of Colorado Cancer Center studies published this month show that the milk thistle extract, silibinin, kills skin cells mutated by UVA radiation and protects against damage by UVB radiation - thus protecting against UV-induced skin cancer and photo-aging.

31 Jan 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Researchers determine precise configuration of humulones

Researchers employing a century-old observational technique have determined the precise configuration of humulones, substances derived from hops that give beer its distinctive flavor.

30 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

AvidBiologics Inc., a life sciences company developing antibody-drug conjugates (ADCs), announces the conclusion of an agreement with the National Research Council Canada (NRC) to develop three novel ADCs for the treatment of cancer.

30 Jan 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

Therapeutics News and Research

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

Study provides new insight on cancer prevention

Study shows how placental circulation can influence malarial parasite behavior and infection

Two new methods could accelerate development of improved antisense drugs

Study shows how female steroid hormones can make changes to the breast genetic material

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Gene variant boosts ulcer susceptibility in NSAID users

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Silibinin kills skin cells mutated by UVA radiation and protects against cancer

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Researchers determine precise configuration of humulones

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Phenformin decreases size of lung tumors and increases survival in mice

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Study sheds light on why enticing pictures of food affect us less when we are full

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News